Sanofi (SNY) Receivables - Other (2016 - 2025)
Sanofi (SNY) has disclosed Receivables - Other for 11 consecutive years, with $1.7 billion as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 11.49% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 11.49% year-over-year, with the annual reading at $1.7 billion for FY2025, 6.84% up from the prior year.
- Receivables - Other hit $1.7 billion in Q4 2025 for Sanofi, up from $1.5 billion in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $1.7 billion in Q4 2025 to a low of $336.7 million in Q4 2022.
- Historically, Receivables - Other has averaged $1.2 billion across 5 years, with a median of $1.5 billion in 2024.
- Biggest five-year swings in Receivables - Other: tumbled 63.44% in 2022 and later soared 362.74% in 2023.
- Year by year, Receivables - Other stood at $920.9 million in 2021, then crashed by 63.44% to $336.7 million in 2022, then skyrocketed by 362.74% to $1.6 billion in 2023, then dropped by 0.82% to $1.5 billion in 2024, then grew by 11.49% to $1.7 billion in 2025.
- Business Quant data shows Receivables - Other for SNY at $1.7 billion in Q4 2025, $1.5 billion in Q4 2024, and $1.6 billion in Q4 2023.